- Home
- AGRO vs SNDX Comparison
AGRO vs SNDX Comparison
Compare AGRO & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGRO
- SNDX
- Stock Information
- Founded
- AGRO 2002
- SNDX 2005
- Country
- AGRO Luxembourg
- SNDX United States
- Employees
- AGRO N/A
- SNDX N/A
- Industry
- AGRO Farming/Seeds/Milling
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- AGRO Consumer Staples
- SNDX Health Care
- Exchange
- AGRO Nasdaq
- SNDX Nasdaq
- Market Cap
- AGRO 1.1B
- SNDX 1.1B
- IPO Year
- AGRO 2011
- SNDX 2016
- Fundamental
- Price
- AGRO $9.22
- SNDX $10.54
- Analyst Decision
- AGRO Hold
- SNDX Strong Buy
- Analyst Count
- AGRO 4
- SNDX 11
- Target Price
- AGRO $11.60
- SNDX $35.91
- AVG Volume (30 Days)
- AGRO 721.5K
- SNDX 3.2M
- Earning Date
- AGRO 05-12-2025
- SNDX 05-05-2025
- Dividend Yield
- AGRO 3.79%
- SNDX N/A
- EPS Growth
- AGRO N/A
- SNDX N/A
- EPS
- AGRO 0.62
- SNDX N/A
- Revenue
- AGRO $1,582,638,000.00
- SNDX $43,722,000.00
- Revenue This Year
- AGRO $0.53
- SNDX $333.70
- Revenue Next Year
- AGRO $0.39
- SNDX $118.66
- P/E Ratio
- AGRO $14.88
- SNDX N/A
- Revenue Growth
- AGRO 20.41
- SNDX N/A
- 52 Week Low
- AGRO $8.45
- SNDX $8.58
- 52 Week High
- AGRO $12.08
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- AGRO 42.82
- SNDX 46.95
- Support Level
- AGRO $9.34
- SNDX $9.73
- Resistance Level
- AGRO $9.60
- SNDX $10.75
- Average True Range (ATR)
- AGRO 0.24
- SNDX 0.73
- MACD
- AGRO 0.10
- SNDX 0.11
- Stochastic Oscillator
- AGRO 59.09
- SNDX 71.01
About AGRO Adecoagro S.A.
Adecoagro SA is a Luxembourg-based agricultural company. It is involved in a wide range of businesses, including farming crops and other agricultural products, dairy operations sugar, ethanol, energy production, and land transformation. The company operates through three segments namely Farming, Sugar, Ethanol and Energy, and Land Transformation. The Farming segment consists of planting, harvesting, and sale of grains, oilseeds and fibers, rice, and production and sale of dairy products; the Sugar, Ethanol, and Energy segment consists of cultivating sugar cane which is processed in owned sugar mills, transformed into ethanol; and the Land Transformation segment comprises identification and acquisition of underdeveloped and undermanaged farmland.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.